EU well-established use (WEU): the new reference product test for bibliographic applications
If a reference product is on the EU market, your WEU route is closed.
Article 14 of the agreed directive text keeps the 10-year well-established use route, but only where no reference product has ever been authorised in the EU for the substance, where one is authorised but not on the EU market at submission, or for herbal products covered by a Union herbal monograph. Pipeline teams need an eligibility check before committing to a dossier.
The literature shortcut is closing
Well-established use lets you register on at least 10 years of published literature, with no new non-clinical or clinical studies.
No test for whether a reference product exists. Eligibility turns on 10 years of well-established use with recognised efficacy and acceptable safety.
A reference product authorised in the EU and on the market at submission closes the route. Generic, hybrid or full application instead.
The route stays open where no reference product has ever been authorised in the EU, where one is authorised but not marketed in the EU, or for herbal products covered by a Union herbal monograph.
One marketed reference product anywhere in the EU closes the route
WEU is an efficient path for well-understood substances. Art. 14 adds an EU-wide reference product test.
10yr
Minimum well-established use in the EU for the same therapeutic use and route of administration, unchanged
1
Reference product authorised in the EU and on the market anywhere in the EU at submission is enough to close the route
4 years
Orphan market exclusivity for an orphan medicine authorised on bibliographic data, against nine years as standard
From broad eligibility to a gated route
Art. 14 keeps the WEU evidence test and adds a reference product gate, which makes market monitoring part of eligibility.
Eligibility criterion
At least 10 years' well-established use in the EU with recognised efficacy and acceptable safety (Art. 10a). No test for reference products.
Same 10-year test, plus a gate: no reference product ever authorised in the EU, or one authorised but not on the EU market at submission, or a herbal product with a Union herbal monograph (Art. 14).
Reference product impact
Reference products matter for the generic route but don't exclude WEU applications.
A reference product authorised and marketed anywhere in the EU excludes WEU. An EU-wide check of authorisation and market status is needed before committing.
Alternative routes
Applicants could choose WEU or generic/hybrid based on commercial strategy.
Where Art. 14 closes WEU, applicants use a generic (Art. 10), hybrid (Art. 11) or full application. Route migration planning is essential.
Ongoing monitoring
No reason to monitor reference product status for a WEU submission.
Eligibility is tested at submission, so a reference product launched during dossier preparation can close the route.
The agreed text is not yet published in the Official Journal. Application dates will be fixed by the published act.
Check the WEU route before you commit
Workbench answers Art. 14 eligibility questions with the agreed text cited. Atlas keeps your planned submissions and their dates, and Alerts catches guidance on how the test is applied.
What's up next?We're two years into a WEU application. A competitor just received a national MA for the same substance in Slovenia. Are we still eligible under the new directive?
- understanding your question…
WEU eligibility · current rules against the agreed text
- Based on the agreed text, which is not yet in the Official Journal. Dates count from entry into force.
1. Short answer
An authorisation alone doesn't close the route; a reference product on the EU market at submission does. If you submit before the new rules apply, the application is completed under Directive 2001/83/EC.
2. What changes
3. What to do now
- Check whether the competitor's product is on the market in any Member State.
- Confirm your submission date against the date the new rules apply.
- Scope a generic or hybrid route in case the WEU route closes.
Workbench
Answers Art. 14 eligibility questions against the agreed text, cites the public sources it used, and reviews dossier readiness when you attach your bibliography or draft sections.
See WorkbenchAtlas
Keeps each planned application on the timeline with an owner, status and submission date, so you can see which will go in before the new rules apply.
See AtlasAlerts
Watches EMA and national authorities for guidance on how availability under Art. 14 is assessed and other WEU notices, and matches each one to the products it affects.
See AlertsA 30-minute live walkthrough of Atlas, Alerts and Workbench, on your own products and markets
The WEU route is narrowing
As reference products reach the EU market, the pool of WEU-eligible substances shrinks.
Art. 221(1)
Applications submitted before the new rules apply, and still pending then, are completed under Directive 2001/83/EC
Agreed directive text
12–18mo
Dossier preparation window we plan for, during which a reference product launch can close the route
Regunaut planning assumption
Art. 111(4)
Generic and WEU products submit PSURs only where the MA requires it or an authority asks, so the route stays lighter after grant
Agreed directive text
What teams are asking about WEU under Art. 14
What do 'authorised' and 'on the market' mean under Art. 14?
The route is open if no reference product has ever been authorised in the EU for the substance. If one has been authorised, the route stays open only while it is not available on the EU market when you submit. An authorisation alone doesn't close it; an authorised product on the market does. Guidance may clarify how availability is assessed.
Does 'anywhere in the EU' include small Member States?
Yes. The test is EU-wide: a reference product on the market in any Member State, including under a national authorisation, closes the route for your application.
We have a WEU application in preparation. Does Art. 14 affect it?
Applications submitted before the new rules apply, and still pending then, are completed under Directive 2001/83/EC (Art. 221(1)). If you will submit after that date, screen under the new test now; the calendar date will be fixed by the published act.
Which alternative route if WEU is no longer eligible?
Depends on the substance: generic (Art. 10) where bioequivalence data are available, hybrid (Art. 11) for differences in strength, route or indication, or a full application.
Can WEU eligibility differ by EU country?
No. The Art. 14 test looks at the whole EU. If a reference product is authorised and on the market anywhere in the EU, the route is closed for your application in every Member State.
Related reading
- Choosing between WEU, generic and hybrid routes is part of loss-of-exclusivity and market entry planning.
- When the generic route opens depends on the reference product's data exclusivity period.
- For a short definition of the route itself, read the glossary entry on well-established use.
- WEU eligibility is one of ten changes covered in our guide to the new EU pharmaceutical directive.
- Dates that depend on publication are tracked on the EU pharma package legislative timeline.
Sources
Article numbers refer to the Council's position at first reading of 28 September 2026 (ST 7106/2/26 REV 2 for the directive, ST 7105/2/26 REV 2 for the regulation), which reflects the political agreement of December 2025. Numbering may change in the act published in the Official Journal.
- Council of the EU: Directive on the Union code relating to medicinal products for human use, Council position at first reading, 28 September 2026 (ST 7106/2/26 REV 2), Articles 14, 111 and 221
- Council of the EU: Regulation laying down Union procedures for the authorisation and supervision of medicinal products, Council position at first reading, 28 September 2026 (ST 7105/2/26 REV 2), Article 73
- EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use (Article 10a, well-established use)
- European Commission: EudraLex Volume 2, Notice to applicants for medicinal products for human use
- Council of the EU: 'Pharma package': Council and Parliament reach a deal (press release, 11 December 2025)
- Council of the EU: The pharma package, new EU rules on medicines (policy page)
- European Commission: Reform of the EU pharmaceutical legislation
- EUR-Lex: Procedure 2023/0132/COD, Directive on the Union code relating to medicinal products for human use (COM(2023) 192)
- EUR-Lex: Procedure 2023/0131/COD, Regulation on Union procedures for the authorisation and supervision of medicinal products (COM(2023) 193)
Know your WEU position before you commit to a dossier
A reference product that reaches the market during dossier preparation can close the route. Check eligibility for each pipeline substance before you commit, and again before you submit.
Book a WEU walkthrough
30 minutes on your own pipeline: which WEU applications are exposed under Art. 14, and how Workbench, Atlas and Alerts keep track of them.
Book a demoAsk Workbench yourself
Put your WEU eligibility questions to Workbench and get answers that cite the agreed text and guidance.
Try for free